U.S. Water Utilities Stock News

NCR Voyix recently reported that it has retained its No. 1 global position in POS software installations across retail, reclaimed the top spot in new restaurant deployments, and reinforced its leadership in Grocery+ and convenience sectors. Alongside this industry leadership, the company’s latest quarterly results showed stronger recurring software and services revenue with improved profitability margins, reflecting progress in its platform-led, AI-enabled digital commerce strategy. Now,...

BioCryst Pharmaceuticals (BCRX) just picked up a meaningful catalyst, with the FDA clearing an oral pellet version of Orladeyo for children aged 2 to under 12 with hereditary angioedema, opening a newly addressable niche. See our latest analysis for BioCryst Pharmaceuticals. Despite this catalyst, BioCryst’s 1 year total shareholder return of around minus 2 percent and a 3 month share price return of roughly minus 10 percent suggest momentum has been fading, even as management pursues the...

Range Resources (RRC) just extended its streak of outperforming earnings expectations, backed by effective natural gas hedging that is helping smooth out commodity price swings and, in turn, lifting investor confidence in the story. See our latest analysis for Range Resources. Even after today’s 1 day share price return of 2.82 percent, Range’s stock is still down on a 1 month share price basis. However, its 5 year total shareholder return of 399.01 percent shows the longer term momentum...

SharpLink Gaming, Inc. recently completed a planned leadership transition appointing Joseph Chalom as CEO, while expanding its institutional-grade Ethereum treasury platform by more than doubling its ETH holdings and updating corporate bylaws. By increasing institutional ownership to over 30% and emphasizing Ethereum treasury management, the company is repositioning itself as a specialized, crypto-focused treasury operator within the broader digital asset ecosystem. Next, we’ll examine how...

Syndax Pharmaceuticals (SNDX) is back on traders radar after showcasing fresh data on its FDA approved cancer drugs Revuforj and Niktimvo at the high profile ASH hematology meeting in Orlando. See our latest analysis for Syndax Pharmaceuticals. The momentum around these ASH updates lines up with a strong run in the stock, with Syndax delivering a roughly 44% year to date share price return and a 59% total shareholder return over the last year, even as multi year total shareholder returns...

Expedia Group (EXPE) is back on investors radar after a stronger than expected third quarter, where earnings and demand outpaced forecasts and helped drive a 17.6% jump in the stock over the past month. See our latest analysis for Expedia Group. That surge has capped a strong run, with a roughly 16% 30 day share price return and a robust 1 year total shareholder return of about 62%, suggesting momentum is clearly building as investors reassess Expedia Group’s growth prospects and perceived...

Nasdaq, Inc. recently moved to extend U.S. equity trading to 23 hours a day on its venues, filing with the SEC for an additional overnight session and outlining operational readiness for the expanded schedule by 2026. This push toward near-continuous trading highlights Nasdaq’s effort to reshape access to U.S. markets, particularly for global and after-hours investors, while reinforcing its identity as a technology-driven market operator. We’ll now explore how Nasdaq’s 23-hour trading push...

Veralto (VLTO) just gave income investors something to chew on, with its board approving an 18% bump to the quarterly dividend. The payout is now set at 0.13 dollars per share and scheduled for payment in late January. See our latest analysis for Veralto. The move comes as Veralto’s share price sits around 100.05 dollars, with a modest positive 30 day share price return but a weaker 1 year total shareholder return. This suggests momentum is still rebuilding as investors reassess its growth...

Medical Properties Trust (MPW) just raised its quarterly dividend by more than 12%, while signing a new lease for six California hospitals, a one two punch aimed at calming nerves around cash flow and tenant risk. See our latest analysis for Medical Properties Trust. Even with a choppy patch that saw a 7 day share price return of minus 9.26 percent, Medical Properties Trust still reports a year to date share price return of 24.38 percent and a 1 year total shareholder return of 36.19 percent...

Ocular Therapeutix (OCUL) just sped up the playbook for its lead eye drug by planning to file an FDA application for AXPAXLI in wet AMD based on positive year one SOL-1 Phase 3 data. See our latest analysis for Ocular Therapeutix. The pivot to an earlier NDA comes as Ocular Therapeutix trades at $13.72, with a 1 month share price return of 16.67 percent and a year to date share price return of 56.98 percent, while its 3 year total shareholder return of 395.31 percent signals strong long term...

SS Innovations International (SSII) just hit a key milestone by filing a 510(k) submission with the FDA for its SSi Mantra surgical robot, aiming for faster, potentially lower cost entry into the US market. See our latest analysis for SS Innovations International. That progress comes after a choppy run, with a 1 day share price return of 6.7 percent and a 1 year total shareholder return of 17.4 percent suggesting momentum is starting to rebuild from a lower base. If this kind of medtech story...

CBRE Group (CBRE) is back in the spotlight after a string of upbeat analyst calls and fresh leadership moves, prompting investors to revisit how its evolving business mix might influence performance in 2026. See our latest analysis for CBRE Group. Those leadership promotions and the Pearce Services acquisition are landing against a solid backdrop, with a roughly 23 percent year to date share price return and a powerful five year total shareholder return of about 155 percent, suggesting...

Earlier in December 2025, GlaxoSmithKline notified IDEAYA Biosciences that it will terminate their 2020 collaboration and license agreement, returning the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs to IDEAYA within about 90 days. This shift hands IDEAYA full control of two oncology assets while the company maintains its guidance that cash resources should last into 2030. Next, we’ll examine how GSK’s exit from the collaboration reshapes IDEAYA’s investment narrative,...

If you are wondering whether Oracle at around $178 a share is still a smart buy or if the easy money has already been made, this article will walk through what the numbers really say about its value. Despite a sharp pullback in the short term, with the stock down about 20% over the last week and 18.8% over the past month, Oracle is still up 7.5% year to date and has delivered an impressive 193.0% gain over five years. Recent headlines have focused on Oracle doubling down on cloud...

Wondering if Ally Financial at around $44 a share is still a value play after its big run, or if most of the upside is already priced in, you are not alone. The stock has climbed 18.4% over the last month, 24.8% year to date, and an impressive 106.8% over three years, which naturally raises questions about how much of the future has been pulled forward. Recent headlines have focused on Ally sharpening its digital banking strategy and doubling down on auto and consumer lending, while also...

Kanzhun Limited has reshuffled its leadership, with Chief Financial Officer and executive Director Phil Yu Zhang stepping down from those roles on December 11, 2025 to become Chief Strategy Officer, while Wenbei Wang becomes Deputy CFO and Yang Mu joins the board as an executive Director. This move shifts a long-serving finance leader into a forward-looking strategy role while elevating investor relations and human resources executives into more influential positions. We’ll now examine how...

Lennar (LEN) has just wrapped up FY 2025 with fourth quarter revenue of about $9.4 billion and basic EPS of $1.94, setting the tone for a year in which trailing twelve month revenue came in at roughly $34.2 billion alongside EPS of $8.06. The company has seen quarterly revenue move from around $9.9 billion in Q4 2024 to $9.4 billion in Q4 2025, while basic EPS shifted from $4.06 to $1.94 over the same stretch, leaving investors focused on how much of that topline scale is now flowing through...

Core Scientific (CORZ) has been under pressure lately, with the stock sliding about 8% in the past month and nearly 19% over the past 3 months, raising valuation questions for crypto-focused investors. See our latest analysis for Core Scientific. Zooming out, that recent volatility sits within a choppy year, with the latest 1 year total shareholder return of around minus 6 percent and year to date share price return also modestly negative. This suggests momentum has cooled even as revenue...

In recent days, Strategy Inc disclosed that it bought 10,645 Bitcoin for about US$980.3 million, lifting its holdings to 671,268 BTC, largely financed through common and preferred stock issuance. This aggressive accumulation is sharpening debate over Strategy’s identity as either a Bitcoin treasury vehicle or a software and services operating company, with index providers scrutinising its eligibility. We’ll now examine how this equity-funded Bitcoin buying spree, and the resulting concerns...

CommScope Holding Company (COMM) has quietly staged a sharp turnaround, with shares up about 2,444% year to date and nearly 1,900% over the past year, catching many investors off guard. See our latest analysis for CommScope Holding Company. That surge has cooled a bit recently, with a 7 day share price return of negative 11.77 percent and a 30 day share price return of 7.63 percent. However, the 1 year total shareholder return of 189.89 percent still points to powerful momentum as investors...

Earlier in December 2025, FMC Corporation launched “Project Foundation,” a multi-year restructuring that closes higher-cost plants, consolidates production in lower-cost locations, and is expected to cost between US$560 million and US$635 million while targeting US$175 million in annual savings by the end of 2027. At the same time, FMC moved to preserve its balance sheet by cutting its regular quarterly dividend to US$0.08 per share and amending its credit agreement, adding tighter leverage...

Wondering whether Huntington Bancshares is still a buy at today's price, or if the easy gains are already behind it? This breakdown will help you decide, using a clear, valuation-first lens. After a solid run, the stock is up 15.6% over the last month and 15.9% over the past year, adding to a 79.4% gain over five years that has investors asking if it is getting ahead of itself. Recent headlines have focused on Huntington's continued push to grow its regional footprint and deepen customer...

Wondering if MSC Industrial Direct is quietly trading at a bargain or already priced for perfection? This breakdown will help you decide whether the current share price makes sense. The stock has nudged up 2.1% over the last week and 0.4% over the past month, but a 14.4% gain year to date and 14.6% over the last year suggest a steady, rather than explosive, re rating. Recent attention has focused on how MSC is navigating the broader industrial and manufacturing cycle, including shifting...

Portland General Electric (POR) just got hit with a fresh lawsuit in Oregon accusing it of contributing to nitrate contaminated groundwater, a legal twist that could reshape how investors think about the utility’s long term risk profile. See our latest analysis for Portland General Electric. Even with this legal overhang, the stock’s 90 day share price return of 15.4 percent and 1 year total shareholder return of 18.1 percent suggest investors still see improving prospects rather than fading...